Skip to main content

Table 1 Summary of information from studies used in the review

From: The use of the mannitol test as an outcome measure in asthma intervention studies: a review and practical recommendations

Study (publication year) n* Screening PD15 inclusion criterion? Interventions Treatment duration (or gap between measures for repeatability) Original scale DD scale (log2 transformed)
Geometric mean ratio (95% CI) Difference between treatments Within-subject SD Between-subject SD of change
REPEATABILITY: 2 successive PD15 measurements under same conditions, no interventions ND
 Barben et al. (2003) [17] 17  ≤ 635 N/A 2–7 days 1.050
(0.941–1.172)
0.071 0.673
 Udesen et al. (2017) [18] 41 No N/A 6 months 1.225
(0.907–1.652)
0.292 0.598
CROSSOVER: 2 treatments, one post-treatment PD15 measurement for each treatment
 Brannan et al. (2000) [19] 24  < 350 Nedocromil/
Placebo
Single dose 2.625
(1.893–3.641)
1.392 0.791
 Brannan et al. (2001) [20] 20  < 290 Fexofenadine/
Placebo
Single dose 2.696
(1.713–4.242)
1.431 0.988
19  < 290 Montelukast/
Placebo
Single dose 0.825
(0.653–1.043)
− 0.278 0.496
CROSSOVER: 2 treatments, pre and post PD15 measurements for each treatment
 Anderson et al. (2012) [21] 21 No FP 500 mg/
FP 100 mg
2 weeks 1.4
(0.7–3.1)
0.5 1.2
 Clearie et al. (2012) [22] 13  ≤ 635 FP + SM/
FP (smokers)
2 weeks 1.5 0.6 1
11  ≤ 635 FP + SM/
FP (non-smokers)
2 1 0.9
 Brannan et al. (2015) [23] 23  ≤ 315 Fish oil/
placebo
3 weeks 0.76
(0.43 –1.32)
− 0.402 0.94
PARALLEL GROUP: 2 or more treatment groups, pre- and post-treatment PD15 measurements  
 Barakat et al. (2012) [24] 11  ≤ 635 FP 100 mg 7 weeks N/A N/A 1.3 1.61
11 FP 500 mg 0.62
(0.21–1.78)
− 0.7 1.0
 Toennesen et al. (2018) [25] 34 No Control
(no treatment)
8 weeks N/A N/A 0.87 1.36
29 Exercise 0.81
(0.71–0.92)
0.30 1.15
33 Diet 0.92
(0.81–1.05)
− 0.12 0.88
29 Exercise + diet 0.91
(0.78–1.05)
− 0.14 0.90
SINGLE GROUP: Comparing change in PD15 pre- to post-treatment  
 Brannan et al. (2002) [26] 18 Yes
 ≤ 635
Budesonide 6–9 weeks 3.73
(2.87–4.86)
1.90 0.52 0.74
 Koskela et al. (2003)§ [27] 17 Yes
 ≤ 635
Budesonide 6 months 3.6
(1.6–8.4)
1.85 1.7 2.4
 Kersten et al. (2011) [28] 17 No Dropping of LABA 30 days 0.92
(0.64–1.32)
− 0.13 0.73 1.03
  1. Negative tests (PD15 > 635 mg) have a PD15 value of 635 mg imputed for use in calculations, except where noted
  2. DD: dose doubling, FP: fluticasone, LABA long-acting beta2-agonists, N/A not applicable, ND: not determined, RDR response-dose ratio, SD standard deviation, SM salmeterol
  3. *n = subjects used in calculation (may be a subset of total study population)
  4. PD15 data not published—anonymised raw data provided by authors
  5. Approximated from plots in publication
  6. §1270 imputed for negative tests rather than 635 in summary data (no raw data available)